|
WO2021011423A1
|
|
Systems and methods for disease and trait prediction through genomic analysis
|
|
WO2020106971A1
|
|
Systems and methods for enhanced novelty detection
|
|
CA3110199A1
|
|
Systems and methods for enhanced imaging and analysis
|
|
KR20180112024A
|
|
Exogenous gene expression of therapeutic adenoviruses for minimizing the effects on viral dynamics
|
|
KR20170123658A
|
|
Treatment of Adult Latent Autoimmune Diabetes Using Phenesoid X Receptor Agonists to Activate Long Term Receptors
|
|
KR20170116164A
|
|
Reprogramming precursor composition and method of use thereof
|
|
JOP20200230A1
|
|
Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
|
|
US2015307858A1
|
|
Methods and isolated protein compositions for isoprenoid diphosphate synthesis
|
|
KR20160132111A
|
|
Fxr agonists and methods for making and using
|
|
KR20160133529A
|
|
Analogs of fexaramine and methods of making and using
|
|
EP2825649A1
|
|
Selective cell targeting using adenovirus and chemical dimers
|
|
AU2011348220A1
|
|
Cyclic CRF antagonist peptides
|
|
EP2558115A2
|
|
Methods for treating metabolic disorders using fgf
|
|
AU2008345009A1
|
|
Methods for enhancing muscle performance and tone
|
|
AU2008323903A1
|
|
Use of vitamin D receptor agonists and precursors to treat fibrosis
|
|
AU2007341981A1
|
|
Methods for enhancing exercise performance
|
|
AU2007311137A1
|
|
Receptor(SSTR2)-selective somatostatin antagonists
|
|
AU2006200258A1
|
|
Novel steroid-activated nuclear receptors and uses therefor
|
|
AU2003259172A8
|
|
Receptor (sstr4)- selective somatostatin analogs
|
|
AU2003200641B2
|
|
Novel Steroid-activated Nuclear Receptors and Uses therefor
|
